EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in antisense oligonucleotide treatment for cancer

Lu Zhu iD, Pariha Muhtar iD, Susumu Goyama iD, Akihide Yoshimi iD

Japanese Journal of Clinical Oncology · 07.05.2026 · 56 (5) · 503-517

DOI: 10.1093/jjco/hyag017 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 03.02.2026. Verfasst von Lu Zhu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer RNA Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Molecular Targeted Therapy, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Takeda Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNA therapeutics, including antisense oligonucleotides (ASOs), have emerged as a promising class of drugs, with several already approved for clinical use. To date, most approved ASO-based RNA therapies target non-malignant disorders such as neurodegenerative diseases, and only a single therapy in this class has been approved for cancer. Notably, nearly half of existing RNA therapeutics act by modulating RNA splicing. Given the growing evidence implicating aberrant RNA splicing in cancer pathogenesis, the development of ASO-based therapeutics for oncologic indications is expected to accelerate. More than 250 clinical trials have evaluated oligonucleotide agents targeting diverse cancer-associated molecules, with several showing encouraging early results. In this review, we summarize recent advances in understanding cancer biology relevant to ASO-based therapies and highlight ongoing progress in the development of RNA-targeted approaches for cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligonucleotides, AntisenseMolecular Targeted TherapyAntineoplastic AgentsNeoplasmsRNA SplicingClinical Trials as TopicHumansGene SilencingPrecision MedicineAnimals

Stichwörter der Autor:innen

RNA splicingantisenseclinical trialmolecular targeted therapyneoplasmsoligonucleotides

Substanzen

Oligonucleotides, AntisenseAntineoplastic Agents

Autor:innen und Institutionen

  • Division of Cancer RNA Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
  • Department of Cancer Cellular Signaling, Graduate School of Medicine, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
  • Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639, Japan.

ORCID-Profile: Lu Zhu, Pariha Muhtar, Susumu Goyama, Akihide Yoshimi

Förderung

  • Japan Agency for Medical Research and Development
  • Takeda Science Foundation

Zitieren

APA

Zhu, L., Muhtar, P., Goyama, S., & Yoshimi, A. (2026). Advances in antisense oligonucleotide treatment for cancer. Japanese Journal of Clinical Oncology, 56(5), 503-517. https://doi.org/10.1093/jjco/hyag017

Vancouver

Zhu L, Muhtar P, Goyama S, Yoshimi A. Advances in antisense oligonucleotide treatment for cancer. Japanese Journal of Clinical Oncology. 2026;56(5):503-517. doi:10.1093/jjco/hyag017

BibTeX
@article{Zhu2026,
  author = {Zhu, Lu and Muhtar, Pariha and Goyama, Susumu and Yoshimi, Akihide},
  title = {Advances in antisense oligonucleotide treatment for cancer},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2026},
  volume = {56},
  number = {5},
  pages = {503--517},
  doi = {10.1093/jjco/hyag017}
}
Kostenlos starten →